Efficacy and safety of Ustekinumab, a human interleukin-12/-23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). - Papp,K.A.; Langley,R.G.; Lebwohl,M. (Lancet, 2008)